TIL and Anti-PD1 in Metastatic Melanoma

Adverse Drug Event Clinical Trial

— ACTME  

Official title:

Adoptive TIL Therapy With Low-dose IFN-alpha Plus Anti-PD1 in Metastatic Melanoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03638375
• Other study ID #: NL64805.000.18
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: July 31, 2018
• Est. completion date: November 29, 2025

Study information

• Verified date: December 2023
• Source: Leiden University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The ACTME study is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma. The trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL. The treatment with IFN-alpha will be added after the combination of TIL and nivolumab has proven to be safe.

Description:

The ACTME is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma.

Patients are conditioned by low-dose IFN-alpha and treated with ACT and PD-1 antibodies. With this approach the investigators hope to solve 4 of the most important aspects curtailing the efficacy of current immunotherapies in metastatic melanoma:

1. the lack of sufficient numbers of activated tumor-reactive T cells in patients by providing ACT; and

2. the inhibition of T-cell effector function through PD-1 signalling by administration of nivolumab; as well as

3. the toxicity of high-dose IL-2, and

4. long term hospitalization of patients due to the conditioning-regimen used in most ACT protocols by replacing it with low-dose IFN-alpha treatment.

The trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL.

The treatment with IFN-alpha will be added after the combination of TIL and nivolumab has proven to be safe in the first cohort of the phase I part of the trial.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 34
• Est. completion date: November 29, 2025
• Est. primary completion date: November 29, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years

2. Histologically or cytologically proven metastatic skin melanoma

3. Melanoma must be at one of the following AJCC 2009 stages:

• Unresectable (or residual) regional metastatic melanoma, i.e. in terms of AJCC 2009 classification unresectable stage III melanoma, or

• Stage IV melanoma, i.e. distant metastatic disease (any T, any N, M1a, M1b or M1c), and normal LDH

• Patients have failed on standard treatment options

4. Patients with brain metastases have to be neurologically stable for at least 2 months and should not use dexamethasone

5. Presence of measurable progressive disease according to RECIST version 1.1

6. Expected survival of at least 3 months

7. WHO performance status =1

8. Within the last 2 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified:

Lab Parameter Range Hemoglobin = 6,0 mmol/l Granulocytes = 1,500/µl Lymphocytes = 700/µl Platelets = 100,000/µl Creatinine clearance = 60 min/ml Serum bilirubin = 40 µmol/l ASAT and ALAT = 5 x the normal upper limit LDH = 2 x the normal upper limit

9. Viral tests must be performed at least 30 days before surgery:

• Negative for HIV type 1/2, HTLV and TPHA

• No HBV (hepatitis B virus) antigen or antibodies against HBc in the serum

• No antibodies against HCV (hepatitis C virus) in the serum

10. Able and willing to give valid written informed consent.

11. Progressive disease on prior treatment with f.e. BRAF-inhibitors, MEK-inhibitors or immunotherapy, including anti-PD1 treatment. Systemic therapy must have been discontinued for at least four weeks before start of study treatment.

Exclusion Criteria:

1. Patients with brain metastases who are neurologically unstable and/or use dexamethasone

2. Clinically significant heart disease (NYHA Class III or IV)

3. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study

4. Active immunodeficiency disease, autoimmune disease requiring immune suppressive drugs or autoimmune adverse events following treatment with checkpoint inhibitors. Vitiligo is not an exclusion criterion

5. Subjects with a condition requiring systemic chronic steroid therapy (= 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 14 days prior to planned date for first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids, and adrenal replacement therapy are allowed.

6. Other malignancy within 2 years prior to entry into the study, except for treated non-melanoma skin cancer and in situ cervical carcinoma

7. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study

8. Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the associated with the participation, study drug administration, or would impair the ability of the patient to receive protocol therapy

9. Lack of availability for follow-up assessments

10. Pregnancy or breastfeeding

11. Known allergy to penicillin or streptomycin (used during the culturing of T cells)

Related Conditions & MeSH terms

• Adverse Drug Event
• Drug-Related Side Effects and Adverse Reactions
• Effects of Immunotherapy
• Melanoma
• Toxicity, Drug

Intervention

Drug:
• Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10^8 T cells i.v.) once every three weeks for three infusions. In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks.

Locations

Country	Name	City	State
Netherlands	Leiden University Medical Center	Leiden

Sponsors (2)

Lead Sponsor	Collaborator
Leiden University	Bristol-Myers Squibb

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment-related serious adverse events as assessed by CTCAE 4.0 criteria	To evaluate the safety and toxicity of ACT with nivolumab, followed by evaluating the safety and toxicity of IFN-alpha, and nivolumab plus ACT according to the common terminology criteria of adverse events (CTCAE) 4.0 criteria. Treatment related adverse events grade 3 or less and SAE related to treatment that do not result in treatment termination are considered acceptable for continuation of the study.; Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL; Grade 3: Severe or medically significant but not immediately life-threatening hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death related to AE	14 weeks after start of treatment
Secondary	Evaluation of disease control rate according to RECIST 1.1 criteria	Disease control is defined by complete response, partial response or stable according to RECIST 1.1 versus no clinical benefit defined as progressive disease.; Complete response: Disappearance of all target and nontarget lesions, nodes must regress to <10mm short axis, no new lesions, confirmation required Partial response: =30% decrease in tumor burden compared with baseline, confirmation required Progressive disease: =20% + 5 mm absolute increase in tumor burden compared with nadir, appearance of new lesions or progression of nontarget lesions Stable disease: neither partial response nor progressive disease	14 weeks after first nivolumab infusion
Secondary	Evaluation of disease control rate according to immune RECIST response criteria	Disease control is defined by complete response, partial response or stable according to the iRECIST versus no clinical benefit defined as progressive disease.; Complete response: Disappearance of all lesions Partial response: =30% decrease in tumor burden compared with baseline. Progressive disease: =20% + 5 mm absolute increase in tumor burden compared with nadir Stable disease: neither progressive disease nor partial response	14 weeks after first nivolumab infusion
Secondary	To study the potential working mechanisms of the different treatment compounds. Therefore, blood will be drawn to analyse changes in circulating immune cells and their function during treatment.	The investigators will analyse the patients their tumor material, blood, serum and the TILs used for infusion	Within 5 years after first inclusion
Secondary	To establish a possible prognostic biomarker profile in patients tumor material, blood, serum and TILs used for infusion	The investigators will analyse the patients their tumor material, blood, serum and the TILs used for infusion to look at changes in the number and phenotype of circulating immune cells, the cytokines that are produced by these cells and serum/plasma markers of persistence.	Within 5 years after first inclusion
Secondary	To characterize the infusion product	The expression of co-inhibitory molecules on T cells and regulatory T cells will be measured by flow cytometry. Furthermore, the investigators will assess the fraction of tumor-specific TIL, their cytolytic capacity as well as to analyse their persistence in the circulation. The supernatants of T cell are used for cytokine analysis assays.	Within 5 years after first inclusion
Secondary	To analyse potential correlations between the clinical response and hypothesis related immune parameters		Within 5 years after first inclusion
Secondary	To analyse the overall survival following treatment	The overall survival of all patients entering the study will be monitored	Within 5 years after first inclusion